Drugs / VGN-R09b
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05765981 | Jan 2023 → Feb 2025 overdue | aromatic L-amino acid decarboxylase deficiency | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06480461 | Sep 2024 → Sep 2026 overdue | Parkinson disease | Shanghai Vitalgen BioPharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06432140 | Jul 2024 → Jul 2026 overdue | aromatic L-amino acid decarboxylase deficiency | Shanghai Vitalgen BioPharma Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGN-R09b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06432140 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “VGN-R09b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9)” NCT05765981 ↗ |
| Route | Other | “injected into bilateral putamen by stereotactic surgery” NCT05765981 ↗ |